Nano Cap Lisata Therapeutics Bolsters Cardioendocrine Pipeline Strategy
Lisata Therapeutics acquires Marea Therapeutics and secures $225 million in private financing for Phase 2 clinical trials.
Share
Why It Matters
Lisata bought another company and got $225 million in cash. This money helps them test new heart medicines in people.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.